Hester Biosciences logo

Hester Biosciences financials: balance sheet, profit and loss, cash flow

NSE: HESTERBIOBSE: 524669Pharmaceuticals & BiotechnologySmall Cap

Hester Biosciences Limited · Face value ₹10 · Listed Oct 1994 on BSE, Mar 2015 on NSE
Last close ₹2,152.90up ₹94.80 (4.61%)BSE ₹2,143.15

Share price at the NSE close on 27 Oct 2026. Previous close ₹2,058.10.

27 Oct: open ₹2,020.50, high ₹2,190.00, low ₹2,020.50

52-week range of traded prices to 27 Oct 2026
₹1,239.30Low, 30 Mar 2026₹2,683.60High, 30 Jul 2026
Market cap
₹1,831 Cr1,322nd largest listed
P/E
13.45
P/E without one-offs
38.24
P/B
5.08
Dividend yield
0.51%
ROE
40.4%
ROE without one-offs
14.2%
ROCE
11.7%
Debt to equity
0.51
Volume, NSE
1,39935.3% delivered

Hester Biosciences' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Hester Biosciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
12323Mar 1713623Mar 181784181Mar 1918331109Mar 2021435Mar 2123539223Mar 2226628268Mar 2330521239Mar 2431129208Mar 2533357188Mar 26
Peak revenue ₹333 Cr, year to Mar 2026; lowest ₹123 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
38.2%7.0%33.2%34.6%38.2%30.2%32.0%25.5%19.0%17.6%19.6%26.1%19.1%16.9%22.9%16.9%16.2%16.8%10.5%7.0%9.3%17.3%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 0.6% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue333
  2. Materials and goods−82
  3. Employee costs−63
  4. Other expenses−101
  5. Operating profit87
  6. Depreciation−19
  7. Other income+9.7
  8. One-off items+2.9
  9. Finance costs−11
  10. Profit before tax69
  11. Tax−18
  12. Joint ventures+6.4
  13. Net profit57

What the company owns

  • Plant, investments and other assets₹504 Cr
  • Receivables₹95 Cr
  • Inventory₹73 Cr
  • Cash and bank₹7 Cr

What pays for it: net worth and liabilities

  • Net worth₹368 Cr
  • Borrowings₹188 Cr
  • Other liabilities₹97 Cr
  • Owed to suppliers₹25 Cr

Hester Biosciences business segments, year to Mar 2026

A reportable segment is a line of business the company must report on its own. Consolidated, ₹ crore, as the company reports them.Hester Biosciences segment results by quarter

Revenue by segment

₹333 CrTotal
  • Poultry Healthcare₹206 Cr61.9% of total
  • Animal Healthcare₹127 Cr38.1% of total

Profit by segment

  • Poultry Healthcare₹58.1 Cr69.7% of total
  • Animal Healthcare₹25.3 Cr30.3% of total

Segment results by year

Consolidated from the year to Mar 2022, standalone before, ₹ crore, years to March.

  • Poultry Healthcare

    Revenue, ₹ crore
    Profit, ₹ crore
  • Animal Healthcare

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue of all businesses178181208235266305311333
Company revenue, as in its results178183208235266305311333
Revenue130120156172141145167206
Revenue growth–−7.7%––−17.8%2.8%15.3%23.0%
Profit4830395527182758
Profit growth–−37.2%––−50.8%−31.8%46.9%115.3%
Margin36.7%25.0%24.9%31.9%19.1%12.6%16.1%28.2%
Return on capital––23.1%25.6%12.5%8.1%11.0%54.0%
Assets––182236242245261123
Liabilities––142227181716
Capital employed––168214215228244108
Revenue4347–63116133144127
Revenue514––9270–
Revenue––53–––––
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Hester Biosciences quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 9 MayMar 2026Jun 2026Twelve monthsFiled 30 Jul
Revenue from operations123136178183214235266305311333326
8289110128146175215251250246239
Materials and goods bought2923292050637796888277
Employee costs––294139455664626362
Other expenses––52685767829199101100
Operating profit before depreciation4147685569605154618787
Operating margin33.2%34.6%38.2%30.2%32.0%25.5%19.0%17.6%19.6%26.1%26.6%
Materials, % of revenue––16.2%10.8%23.4%26.7%29.1%31.5%28.4%24.6%23.5%
Employee costs, % of revenue––16.2%22.2%18.2%19.3%21.1%21.1%20.1%18.8%19.1%
Other expenses, % of revenue––29.3%36.8%26.4%28.5%30.8%29.8%31.9%30.5%30.8%
Depreciation and amortisation710121313172117171922
Operating profit after depreciation3438564255433036446865
Other income037651415114109
Finance costs347774920131112
Profit before one-off items and tax3136574153533627356762
One-off items0000−30000388
Profit before tax31365741505336273569150
813161015141211111820
Share of profit of joint ventures and associates–––––045467
23234131353928212957137
Other comprehensive income––02–1200−2−3
Total comprehensive income––4033–4030212955134
Net margin19.1%16.9%22.9%16.9%16.2%16.8%10.5%7.0%9.3%17.3%42.0%
Net margin without joint ventures and associates–––––16.6%8.9%5.4%7.9%15.4%–
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2017 and Mar 2018 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 9 MayMar 2026
181206–267289303327368
177201–260280292314360
Share capital99–99999
Reserves169193–251271283306352
Belonging to outside owners of subsidiaries45–7911128
81109–223268239208188
4981–97149106125152
7097–198233254202158
Total assets299384–562670662653678
157227–367442448458469
143158–195228215195209
Net debt3985–197253224201182
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2021, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Filed 9 MayMar 2026
924486564
2632607678
−35−21410−31
Receivables−9−2502−29
Inventories−13−995−4
Payables−1012−44−3
Other working capital−32−2−15
Tax paid−17−8−12−11−14
Capital spending9678242118
Free cash flow−87−54244446
−117−77−23−19−3
11242−26−52−49
Dividends paid99756
Shares bought back00000
Shares issued00000
Net change in cash4−12−1−612
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021.

Per share

Consolidated, ₹ per share, years to March.Hester Biosciences dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 9 MayMar 2026
Earnings per share₹27.56₹27.12₹47.84₹36.44₹40.79₹46.41₹32.96₹24.88₹33.89₹67.57
Diluted earnings per share₹27.56₹27.12₹47.84₹36.44₹40.79₹46.41–₹24.88₹33.89₹67.57
Dividend per share₹5.30₹10.00₹11.00₹6.60₹10.00₹10.00₹8.00₹6.00₹7.00₹11.00
Book value per share––₹208.60₹236.36–₹305.61₹328.82₹343.01₹369.41₹423.46
Dividend payout19.2%36.9%22.5%19.2%24.5%21.6%25.6%27.0%21.7%16.8%
Shareholder yield–––––0.4%0.7%0.6%0.5%0.6%
Market cap at the year end (₹ crore)6521,3831,3167831,6302,3081,2951,1861,0671,071

Ratios

Consolidated, years to March.Hester Biosciences PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 9 MayMar 2026
Revenue growth22.0%10.9%30.5%2.9%16.9%9.6%13.2%14.5%2.2%6.9%
Operating profit growth25.4%15.7%44.0%−18.6%23.9%−12.6%−15.6%6.0%13.8%41.9%
Net profit growth24.2%−1.6%76.4%−23.8%11.9%13.8%−29.0%−24.5%36.2%99.4%
Earnings per share growth–−1.6%76.4%−23.8%11.9%13.8%−29.0%−24.5%36.2%99.4%
––23.4%15.4%–15.1%9.9%6.6%9.1%16.5%
–––−8.0 pts––−5.3 pts−3.3 pts2.5 pts7.4 pts
From the net margin–––−7.5 pts––−6.1 pts−3.8 pts2.8 pts8.1 pts
From asset turnover–––−1.6 pts––0.3 pts0.4 pts0.3 pts1.0 pts
From borrowing–––1.0 pts––0.5 pts0.1 pts−0.7 pts−1.6 pts
Return on capital employed––21.5%13.4%–8.9%5.4%6.7%8.3%12.2%
Cash conversion–––––22.3%84.2%227.4%223.8%111.6%
Interest cover9.79.38.55.78.410.73.21.83.56.2
Debt to equity––0.450.53–0.830.930.790.640.51
Receivable days––65116–861099486105
Inventory days––6421,185–439399288291323
Payable days––111345–105141101122110
Cash conversion cycle, days––596956–420368281255318
Working capital days––153170–203202181161162
Asset turnover––0.590.54–0.420.430.460.470.50
Assets per rupee of net worth––1.691.81–2.162.282.332.171.97
Sales per rupee of plant––1.241.34–0.991.031.271.340.81
Capital spending to depreciation–––––5.773.761.421.230.94
Plant being built, % of plant in use––4.9%54.2%–33.9%56.4%70.2%75.9%–
No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2021, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.4%
Cash from operations against operating profit
74.0%
Measure10 years5 years3 years
Revenue growth, yearly rate12.7%9.2%7.7%
Profit growth, yearly rate11.4%9.9%27.8%
Return on equity, average–11.4%10.7%
Return on capital employed, average–8.3%9.1%
Operating margin, average27.6%21.6%21.1%
Net margin, average15.3%12.2%11.2%
Asset turnover, average–0.460.48
Cash conversion cycle, days, average–328285
Interest cover, average6.75.13.8
Debt to equity, average–0.740.65

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations20917764
Cash from investing−239−45−3
Cash from financing27−127−49
Capital spending2366318
Dividends paid35186
Shares bought back000
Shares issued for cash000
Borrowings raised211200
Borrowings repaid15511936

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––––––688
Altman Z-scorePublished threshold 1.81––9.144.47–6.293.373.473.463.78
Beneish M-scorePublished threshold −1.78––––––−2.07−2.48−2.81−2.57
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––––13.22−0.65−2.54−0.51
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––––0.911.751.64
Receivables growth less revenue growthOur threshold 0 percentage points–––81.45––30.82−15.69−9.1023.39
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––57.71––−11.05−34.610.9910.27
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−3.57––3.58−1.02−0.19−1.39
Assets under construction, years of additionsOur threshold 2 years of additions–––12.78––3.42–17.64–
Effective tax ratePublished threshold 17.16 per cent26.3036.1428.4324.9830.7526.4133.9039.4530.2926.42
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−5.8211.22−3.21−2.056.09
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
7 Sep 2026CARE Ratings LimitedFund-based - LT/ ST-Cash CreditCARE BBB+ / CARE A2Review, UpgradeStable60
7 Sep 2026CARE Ratings LimitedNon-fund-based - LT/ ST-Bank GuaranteeCARE BBB+ / CARE A2Review, UpgradeStable5
7 Sep 2026CARE Ratings LimitedFund-based - LT-External Commercial BorrowingsCARE BBB+Review, UpgradeStable37.87
7 Sep 2026CARE Ratings LimitedFund-based - LT-Term LoanCARE BBB+Review, UpgradeStable10.58
7 Sep 2026CARE Ratings LimitedNon-fund-based - ST-Credit Exposure LimitCARE A2Review, Upgrade0.22
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.